Related Experiment Videos
Vaccination against Helicobacter pylori
1School of Microbiology and Immunology, University of New South Wales, Sydney, Australia.
Abstract:
The initial steps have been taken towards the development of a vaccine against the human gastroduodenal pathogen, Helicobacter pylori. Proof of principle was achieved when mice were protected against challenge with living Helicobacter felis, a close relative of the human pathogen, following oral immunization with H. felis sonicate and the mucosal adjuvant, cholera toxin. Similar results with H. pylori antigen have allowed development of possible human vaccines. Recombinant urease protein has been proposed as a major vaccine candidate, together with the heat-labile toxin of Escherichia coli as the adjuvant. Probably the most significant finding in the early vaccine studies was that immunization of already infected mice resulted in a cure of Helicobacter infection. The possibility of a therapeutic vaccine makes commercial development more attractive, as large populations could be immunized without the potential for development of drug-resistant strains that currently restricts widespread antibiotic use. For advanced societies with powerful economies yet a high prevalence of H. pylori, such as Japan, vaccine development should become a high national health priority.
Insights
Developing a vaccine against Helicobacter pylori shows promise. Oral immunization in mice protected against infection and even cured existing Helicobacter infections, suggesting a potential therapeutic vaccine.
Area of Science:
- Microbiology
- Vaccinology
- Gastroenterology
Background:
- Helicobacter pylori is a significant human gastroduodenal pathogen.
- Current treatments for H. pylori infection face limitations due to potential antibiotic resistance.
- There is a need for effective vaccine strategies against H. pylori.
Purpose of the Study:
- To explore the feasibility of developing a vaccine against Helicobacter pylori.
- To investigate the potential of a therapeutic vaccine for existing H. pylori infections.
Main Methods:
- Oral immunization of mice with Helicobacter felis sonicate and cholera toxin.
- Evaluation of protection against challenge with living Helicobacter felis.
- Assessment of H. pylori antigen and recombinant urease protein as vaccine candidates, with heat-labile toxin of E. coli as adjuvant.
Main Results:
- Mice immunized orally with H. felis sonicate and cholera toxin were protected against challenge.
- Immunization of infected mice resulted in a cure of Helicobacter infection.
- Recombinant urease protein is a potential candidate for human H. pylori vaccines.
Conclusions:
- Proof of principle for an H. pylori vaccine has been achieved.
- The potential for a therapeutic vaccine offers an attractive alternative to antibiotics, avoiding drug resistance.
- Vaccine development for H. pylori should be a public health priority, especially in regions with high prevalence.